Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $1414.6.

  • CureVac's Shares Outstanding (Weighted Average) fell 1469.9% to $1414.6 in Q3 2025 from the same period last year, while for Sep 2025 it was $1414.6, marking a year-over-year decrease of 1469.9%. This contributed to the annual value of $28.8 million for FY2024, which is 52.74% down from last year.
  • According to the latest figures from Q3 2025, CureVac's Shares Outstanding (Weighted Average) is $1414.6, which was down 1469.9% from $30.6 million recorded in Q2 2025.
  • CureVac's Shares Outstanding (Weighted Average)'s 5-year high stood at $30.6 million during Q2 2025, with a 5-year trough of $89.79 in Q1 2022.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $7.3 million, with a median of $859.99 in 2023.
  • As far as peak fluctuations go, CureVac's Shares Outstanding (Weighted Average) crashed by 8799.42% in 2022, and later skyrocketed by 443784547.97% in 2025.
  • Over the past 5 years, CureVac's Shares Outstanding (Weighted Average) (Quarter) stood at $25.7 million in 2021, then decreased by 7.06% to $23.9 million in 2022, then grew by 21.14% to $28.9 million in 2023, then fell by 0.53% to $28.8 million in 2024, then crashed by 100.0% to $1414.6 in 2025.
  • Its Shares Outstanding (Weighted Average) was $1414.6 in Q3 2025, compared to $30.6 million in Q2 2025 and $241.93 in Q1 2025.